Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. SCLC cells are preferentially sensitive to loss of DHODH.
  • Fig. S2. Alternative routes, in addition to de novo pyrimidine synthesis, may contribute to pyrimidine pools in LUAD/PDAC cells.
  • Fig. S3. Human cancer cell lines exhibit variable expression of key enzymes involved in pyrimidine and deoxyribonucleotide synthesis.
  • Fig. S4. RB1 mutation status does not affect sensitivity of RPE cells to brequinar treatment.
  • Fig. S5. Brequinar treatment decreases cell proliferation in LUAD and PDAC cell lines.
  • Fig. S6. Human SCLC tumors exhibit variable DCTD expression.
  • Fig. S7. SCLC cells are sensitive to DHODH inhibition when exposed to physiological concentrations of uridine.
  • Fig. S8. DCTD expression potentially determines brequinar sensitivity in tumors.
  • References (5667)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Gene scores for all screens performed in this study.
  • Data file S2 (Microsoft Excel format). Original data.